| Code | CSB-RA621669MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of ladiratuzumab vedotin, targeting SLC39A6 (also known as LIV-1 or ZIP6), a zinc transporter protein belonging to the SLC39A/ZIP family. SLC39A6 is minimally expressed in normal adult tissues but significantly upregulated in multiple malignancies, including breast, prostate, pancreatic, lung, and ovarian cancers. This transmembrane protein regulates zinc homeostasis and promotes epithelial-mesenchymal transition, cell migration, and metastasis through activation of EGFR-ERK and AKT signaling pathways. SLC39A6 expression is particularly elevated in estrogen receptor-positive and triple-negative breast cancers, where it correlates with lymph node involvement and poor prognosis. Ladiratuzumab vedotin is an antibody-drug conjugate consisting of a humanized anti-SLC39A6 monoclonal antibody linked to the microtubule inhibitor MMAE via a protease-cleavable linker. This biosimilar provides the antibody component alone, enabling researchers to investigate SLC39A6 biology, zinc transporter-mediated signaling pathways, and receptor internalization mechanisms independent of cytotoxic payload effects. It supports studies exploring SLC39A6 as a biomarker for metastatic progression and therapeutic target in oncology research.
There are currently no reviews for this product.